Literature DB >> 34602941

Mammary Chain Irradiation in Left-Sided Breast Cancer: Can We Reduce the Risk of Secondary Cancer and Ischaemic Heart Disease with Modern Intensity-Modulated Radiotherapy Techniques?

Vanessa Figlia1, Cristoforo Simonetto2, Markus Eidemüller2, Stefania Naccarato1, Gianluisa Sicignano1, Antonio De Simone1, Ruggero Ruggieri1, Rosario Mazzola1, Christiane Matuschek3, Edwin Bölke3, Montserrat Pazos4, Maximilian Niyazi4, Claus Belka4, Filippo Alongi1,5, Stefanie Corradini4.   

Abstract

INTRODUCTION: The aim of the present study was to estimate the impact of the addition of internal mammary chain (IMC) irradiation in node-positive left-sided breast cancer (BC) patients undergoing regional nodal irradiation (RNI) and comparatively evaluate excess relative and absolute risks of radiation-induced lung cancer/BC and ischaemic heart disease for intensity-modulated radiotherapy (IMRT) versus 3D conformal radiotherapy (3D-CRT).
METHODS: Four treatment plans were created (3D-CRT and IMRT -/+ IMC) for each of the 10 evaluated patients, and estimates of excess relative risk (ERR) and 10-year excess absolute risk (EAR) were calculated for radiation-induced lung cancer/BC and coronary events using linear, linear-exponential and plateau models.
RESULTS: The addition of IMC irradiation to RNI significantly increased the dose exposure of the heart, lung and contralateral breast using both techniques, increasing ERR for secondary lung cancer (58 vs. 44%, p = 0.002), contralateral BC (49 vs. 31%, p = 0.002) and ischaemic heart disease (41 vs. 27%, p = 0.002, IMRT plans). IMRT significantly reduced the mean cardiac dose and mean lung dose as compared to 3D-CRT, decreasing ERR for major coronary events (64% 3D-CRT vs. 41% IMRT, p = 0.002) and ERR for secondary lung cancer (75 vs. 58%, p = 0.004) in IMC irradiation, without a significant impact on secondary contralateral BC risks.
CONCLUSION: Although IMC irradiation has been shown to increase survival rates in node-positive BC patients, it increased dose exposure of organs at risk in left-sided BC, resulting in significantly increased risks for secondary lung cancer/contralateral BC and ischaemic heart disease. In this setting, the adoption of IMRT seems advantageous when compared to 3D-CRT.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; Internal mammary chain; Ischaemic heart disease; Regional nodal irradiation; Secondary cancer

Year:  2020        PMID: 34602941      PMCID: PMC8436658          DOI: 10.1159/000509779

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.268


  56 in total

1.  Adjuvant radiotherapy and risk of contralateral breast cancer.

Authors:  H H Storm; M Andersson; J D Boice; M Blettner; M Stovall; H T Mouridsen; P Dombernowsky; C Rose; A Jacobsen; M Pedersen
Journal:  J Natl Cancer Inst       Date:  1992-08-19       Impact factor: 13.506

2.  ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.

Authors:  Birgitte V Offersen; Liesbeth J Boersma; Carine Kirkove; Sandra Hol; Marianne C Aznar; Albert Biete Sola; Youlia M Kirova; Jean-Philippe Pignol; Vincent Remouchamps; Karolien Verhoeven; Caroline Weltens; Meritxell Arenas; Dorota Gabrys; Neil Kopek; Mechthild Krause; Dan Lundstedt; Tanja Marinko; Angel Montero; John Yarnold; Philip Poortmans
Journal:  Radiother Oncol       Date:  2015-01-24       Impact factor: 6.280

3.  Reassessing the Time Course for Radiation-Induced Cardiac Mortality in Patients With Breast Cancer.

Authors:  Lawrence B Marks; Timothy M Zagar; Orit Kaidar-Person
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-10-31       Impact factor: 7.038

4.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

Authors:  Paul M Ridker; Julie E Buring; Nader Rifai; Nancy R Cook
Journal:  JAMA       Date:  2007-02-14       Impact factor: 56.272

5.  Regional Nodal Irradiation in Early-Stage Breast Cancer.

Authors:  Timothy J Whelan; Ivo A Olivotto; Wendy R Parulekar; Ida Ackerman; Boon H Chua; Abdenour Nabid; Katherine A Vallis; Julia R White; Pierre Rousseau; Andre Fortin; Lori J Pierce; Lee Manchul; Susan Chafe; Maureen C Nolan; Peter Craighead; Julie Bowen; David R McCready; Kathleen I Pritchard; Karen Gelmon; Yvonne Murray; Judy-Anne W Chapman; Bingshu E Chen; Mark N Levine
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

6.  Variations in lung cancer risk among smokers.

Authors:  Peter B Bach; Michael W Kattan; Mark D Thornquist; Mark G Kris; Ramsey C Tate; Matt J Barnett; Lillian J Hsieh; Colin B Begg
Journal:  J Natl Cancer Inst       Date:  2003-03-19       Impact factor: 13.506

7.  DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer.

Authors:  Lise Bech Jellesmark Thorsen; Birgitte Vrou Offersen; Hella Danø; Martin Berg; Ingelise Jensen; Anders Navrsted Pedersen; Sune Jürg Zimmermann; Hans-Jürgen Brodersen; Marie Overgaard; Jens Overgaard
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

8.  Age at exposure and attained age variations of cancer risk in the Japanese A-bomb and radiotherapy cohorts.

Authors:  Uwe Schneider; Linda Walsh
Journal:  Med Phys       Date:  2015-08       Impact factor: 4.071

9.  Radiotherapy-induced secondary cancer risk for breast cancer: 3D conformal therapy versus IMRT versus VMAT.

Authors:  Boram Lee; Sunyoung Lee; Jiwon Sung; Myonggeun Yoon
Journal:  J Radiol Prot       Date:  2014-04-04       Impact factor: 1.394

10.  A Dosimetric Comparison of Breast Radiotherapy Techniques to Treat Locoregional Lymph Nodes Including the Internal Mammary Chain.

Authors:  A Ranger; A Dunlop; K Hutchinson; H Convery; M K Maclennan; H Chantler; N Twyman; C Rose; D McQuaid; R A Amos; C Griffin; N M deSouza; E Donovan; E Harris; C E Coles; A Kirby
Journal:  Clin Oncol (R Coll Radiol)       Date:  2018-03-02       Impact factor: 4.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.